by Dr. Ed Weber | Dec 6, 2018 | PCa Commentary
It has been one year since the Commentary featured the Axumin PET/CT in the November 2017 issue [control+click link to follow]. A great deal of new research about this scan performance has been published since then. The material in this issue is based on this... by Dr. Ed Weber | Nov 2, 2018 | PCa Commentary
Harnessing our immune system to treat cancer has been an elusive goal for decades. Research in immunotherapy is intense with active study of the newest advances, i.e. checkpoint inhibitors and CAR T cell technology. Checkpoint inhibitors have yielded encouraging... by Dr. Ed Weber | Oct 7, 2018 | PCa Commentary
The conventional National Cooperative Cancer Network (NCCN) risk categories — low-, intermediate-, and high-risk are largely based on the Gleason score as determined by the microscopic appearance of cells and their organization. However, beneath the surface appearance... by Dr. Ed Weber | Sep 6, 2018 | PCa Commentary
Many of the important adverse effects associated with androgen suppression with Lupron, Firmagon, or orchiectomy result from estrogen deficiency. Estimates vary, but 50%, 75%, or as much as 80% of a man’s serum estrogen arises from enzymatic conversion of serum... by Dr. Ed Weber | Jul 31, 2018 | PCa Commentary
Neuroendocrine Prostate Cancer — What is it? Neuroendocrine prostate cancer (NEPC) is a form of the disease which, as best currently understood, arises from standard adenocarcinoma in a process termed “transdifferentiation.” This transformation develops in advanced... by Dr. Ed Weber | Jul 12, 2018 | PCa Commentary
The goal of active surveillance (AS) is to delay treatment, avoiding its associated adverse effects for as long as appropriate, while insuring that selective delayed intervention will still result in a good outcome. This management strategy has been under development...